Akero Therapeutics/AKRO

$20.76

1.21%
-
1D1W1MYTD1YMAX

About Akero Therapeutics

Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

Ticker

AKRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Cheng

Employees

55

Headquarters

South san francisco, United States

AKRO Metrics

BasicAdvanced
$1.48B
Market cap
-
P/E ratio
-$2.85
EPS
-0.31
Beta
-
Dividend rate
$1.48B
-0.31184
$58.38
$11.25
1.38M
29.274
4.664
4.664
-32.4%
-35.22%
-33.78%
2.25
2.76
2.63%

What the Analysts think about AKRO

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
145.66% upside
High $60.00
Low $42.00
$20.76
Current price
$51.00
Average price target

AKRO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-55.1M
39.14%
Profit margin
0%
-

AKRO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.95%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.55
-$0.60
-$0.71
-$0.99
-
Expected
-$0.67
-$0.63
-$0.68
-$0.86
-$1.01
Surprise
-18.15%
-4.46%
4.22%
14.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Akero Therapeutics stock?

Akero Therapeutics (AKRO) has a market cap of $1.4B as of April 21, 2024.

What is the P/E ratio for Akero Therapeutics stock?

The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of April 21, 2024.

Does Akero Therapeutics stock pay dividends?

No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Akero Therapeutics dividend payment date?

Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Akero Therapeutics?

Akero Therapeutics (AKRO) has a beta rating of -0.29. This means that it has an inverse relation to market volatility.

What is the Akero Therapeutics stock price target?

The target price for Akero Therapeutics (AKRO) stock is $51, which is 145.66% above the current price of $20.76. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Akero Therapeutics stock

Buy or sell Akero Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing